CN103772411A - Chemical compound containing sulphur-6-furyl chinazoline-4-amine and preparation method and application thereof - Google Patents
Chemical compound containing sulphur-6-furyl chinazoline-4-amine and preparation method and application thereof Download PDFInfo
- Publication number
- CN103772411A CN103772411A CN201310156310.8A CN201310156310A CN103772411A CN 103772411 A CN103772411 A CN 103772411A CN 201310156310 A CN201310156310 A CN 201310156310A CN 103772411 A CN103772411 A CN 103772411A
- Authority
- CN
- China
- Prior art keywords
- compound
- quinazoline
- furyl
- cancer
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Abstract
The invention belongs to the field of medicine synthesis, relates to a chemical compound containing sulphur-6-furan group chinazoline-4-amine with a general formula (I) shown in the Specification, in particular to a N-[3-chlorine-4-[(3-fluorophenyl) methoxyl] phenyl]-6-(2-furyl) chinazoline-4-amine chemical compound with a sulpho-quaternary heterocycle or a loop-coil structure, and a preparation method and medical application thereof. An external anti-tumour activity test result shows that the chemical compound has good anti-tumour acitivity, and can be further prepared into a new anti-tumour medicine.
Description
Technical field
The invention belongs to the synthetic field of medicine, relate to new sulfur-bearing 6-furyl quinazoline-4-amine compound, preparation method and application.Be specifically related to a kind of chloro-4-[(3-fluorophenyl of N-[3-containing sulfo-quaternary heterocycle or spirane structure) methoxyl group] phenyl]-6-(2-furyl) quinazoline-4-amine compound, and preparation method thereof and in application medically.
Background technology
Malignant tumour has become the common disease of serious harm people's life health.According to incompletely statistics, the whole world approximately has 2,000 ten thousand new cases every year; The annual new cases of China are about 160-200 ten thousand, and dead 1,300,000.Because tumour has the ability of transfer in early days, in clinical diagnosis primary tumo(u)r, approximately 50% patient has produced amphi position transfer, tumor cell growth soon, easily variation, thereby generation multidrug resistance, cause chemotherapy failure, according to the relevent statistics, wherein more than 90% relevant to the multidrug resistance of tumour cell, the antitumor drug of applying clinically at present far can not meet the requirement for the treatment of.
EGF-R ELISA (EGFR) belongs to one of Tyrosylprotein kinase receptor family member, comprises HER1(erbB1, EGFR), HER2(erbB2, NEU), HER3(erbB3) and HER4(erbB4).The physiological processs such as EGFR is distributed widely in the cell surfaces such as Mammals epithelial cell, inoblast, spongiocyte, keratinocyte, growth, propagation and the differentiation of EGFR signal path to cell play an important role.Research shows to exist high expression level or the unconventionality expression of EGFR in many noumenal tumours.EGFR is relevant with propagation, vasculogenesis, tumor invasion, transfer and the apoptotic inhibition of tumour cell.The expression of crossing of EGFR plays an important role in the evolution of malignant tumour, has crossing of EGFR to express in the tissues such as spongiocyte, kidney, lung cancer, prostate cancer, carcinoma of the pancreas, mammary cancer.Therefore, in the past more than 20 year, drugmaker and biotech company be the main target spot using EGF-R ELISA as oncotherapy always.
For the tumour molecular targeted agents of EGFR, be mainly divided into two large classes by its character: a class is monoclonal antibody, as Cetuximab, Victibix, Buddhist nun's trastuzumab etc.; Another kind of is micromolecular inhibitor, as Gefitinib, Tarceva and La Pafeini etc.Wherein the mechanism of action of micromolecular inhibitor is mainly by the phosphorylation site of competitive binding EGFR born of the same parents inner segment Tyrosylprotein kinase, blocks itself and the interaction of ATP, and a series of signal of tyrosine phosphorylation and downstream that then suppresses EGFR conducts.
Wherein lapatinibditosylate is developed the oral two target spot tyrosine kinase inhibitors of a class by GlaxoSmithKline PLC company, can act on two target spots of EGFR and HER-2 simultaneously.Gone on the market by U.S. FDA approval in March, 2007.The indication of checking and approving is at present to treat failed late period or transitivity breast cancer with capecitabine combination therapy for first-line drug.Lapatinibditosylate is a kind of Tyrosylprotein kinase double inhibitor of 4-aniline quinazoline class, can be with the reversibly combination of ATP site in EGFR/HER-2 Tyrosylprotein kinase district, suppress the autophosphorylation in receptor kinase district, thus MARK and the PI3K/AKT path in blocking-up downstream.
Although the small molecules EGFR inhibitor medicaments having gone on the market has shown preferably curative effect, because toxic side effect is more, medication effect is undesirable separately, and the problems such as medicament-resistant mutation easily occur.Given this, present inventor intends providing new molecular targeted small molecules antitumor drug safely and effectively.
Summary of the invention
The object of this invention is to provide novel sulfurized 6-furyl quinazoline-4-amine compound with good anti-tumor activity, be specifically related to a kind of chloro-4-[(3-fluorophenyl of N-[3-containing sulfo-quaternary heterocycle or spirane structure) methoxyl group] phenyl]-6-(2-furyl) quinazoline-4-amine compound.
Another object of the present invention is to provide the preparation method of above-mentioned sulfur-bearing 6-furyl quinazoline-4-amine, relates in particular to the N-[3-chloro-4-[(3-fluorophenyl of preparation containing sulfo-quaternary heterocycle or spirane structure) methoxyl group] phenyl] method of-6-(2-furyl) quinazoline-4-amine compound.
Sulfur-bearing 6-furyl quinazoline-4-amine compound of the present invention has the structure of following logical formula I:
Wherein X=H or S or SO or SO
2,
Y=H or S or SO or SO
2.
In the present invention, preferred compound has the structure of following compound 1,2,3,4,5,6:
1
2
3
4
5
6
Take compound 1 as example, the preparation process of compound of the present invention is as follows:
Compound of the present invention is by EGFR and the test of HER-2 kinase inhibiting activity and anti tumor activity in vitro test, result shows, described compound has good EGFR and HER-2 kinase inhibiting activity and anti-tumor activity, can further develop as new antitumor drug.
The present invention suppresses active testing to epidermal growth factor recipient tyrosine kinase EGFR and HER-2, result demonstration, and in the present invention, compound demonstrates good EGFR and HER-2 kinase inhibiting activity, and compound 2 and 3 is for EGFR kinase inhibiting activity IC
50value is less than 20nM, and compound 2 is for HER-2 kinase inhibiting activity IC
50value is less than 7nM, is better than positive control antitumor drug lapatinibditosylate.Compound of the present invention can further be developed EGFR/HER-2 kinase inhibitor.
The present invention studies by Pharmacodynamic, NCI-N87 stomach cancer cell, BT-474 breast cancer cell and SKBr-3 breast cancer cell are carried out to anti tumor activity in vitro test, result shows, in the present invention, compound is for NCI-N87 stomach cancer cell, BT-474 breast cancer cell and SKBr-3 breast cancer cell are had compared with powerful antitumor activity, IC
50value is nM level, and wherein compound 2 is for the extracorporeal anti-tumor IC of NCI-N87 stomach cancer cell
50value is 12nM, and compound 1-6 is for the extracorporeal anti-tumor IC of BT-474 breast cancer cell
50value is all less than 1.6nM, and compound 2 is for the extracorporeal anti-tumor IC of SKBr-3 breast cancer cell
50value, for 15.3nM, is better than positive control antitumor drug lapatinibditosylate,, can further develop new type antineoplastic medicine.
In the present invention, the pharmacodynamics test method adopting, is method well-known to those skilled in the art;
In the present invention, EGF-R ELISA (EGFR/HER-2) Tyrosylprotein kinase adopting and cancer of the stomach and breast cancer tumour strain are that art technology can obtain by commercial approach.
The chloro-4-[(3-fluorophenyl of N-[3-containing sulfo-quaternary heterocycle or spirane structure of the present invention) methoxyl group] phenyl]-6-(2-furyl) quinazoline-4-amine compound especially can prepare treatment malignant tumor medicine, in view of tyrosine kinase receptor is the transmembrane protein participating on cytolemma that cell signal transforms.They have controls such as Growth of Cells, variation, and the growth factor signal of the critical functions such as vasculogenesis and inhibited apoptosis, passes in cell from cell surface.Tyrosine kinase receptor is wherein EGF-R ELISA (EGFR) Tyrosylprotein kinase, the overexpression in many human tumors of these acceptors, as brain, lung, kidney, liver, bladder, stomach, pancreas, mammary gland, incidence, esophagus, prostate gland, colon, ovary, uterine cervix or Tiroidina.Therefore, malignant tumour of the present invention comprises the related neoplasms due to Tyrosylprotein kinase functional disorder, comprises the cancer of the brain, lung cancer, kidney, osteocarcinoma, liver cancer, bladder cancer, cancer of the stomach, carcinoma of the pancreas, mammary cancer, incidence cancer, esophagus cancer, prostate cancer, colorectal carcinoma, ovarian cancer, cervical cancer or thyroid carcinoma.
Embodiment
Embodiment 1: synthetic compound 1, the chloro-4-of N-[3-(3-fluorine benzyloxy)-phenyl]-6-[5-[(2-thia-6-aza-spiro [3,3] heptane-6-yl) methyl]-furans-2-yl]-quinazoline-4-amine
1) synthetic 6-iodine quinazoline-4-one
Methane amide (5ml) solution of 2-amino-5-iodo-benzoic acid (1g, 3.8mmol) is warming up to 120 ℃ and stirs 4h.Be chilled to room temperature, dilute with 50% ethanol (10ml).Filter, filter cake is used respectively 50% ethanol (5ml), EtOH/PE(1:1,10ml), PE(5ml) washing, vacuum-drying, obtains drabon look solid product (0.9g, 93%).
2) the synthetic chloro-6-iodine of 4-quinazoline
In dry toluene (2ml) solution of 6-iodine quinazoline-4-one (0.54g, 2mmol), add phosphorus oxychloride (0.37g, 2.4mmol), under nitrogen protection, drip triethylamine (0.24g, 2.4mmol), after dripping off, rise to 80 ℃ of leopard lines and stir 2.5h.Reaction solution is cooled to 2 ℃ and stirs 1h, filters.Filter cake washing with acetone, then use 1mol/L aqueous sodium hydroxide solution (3ml) washing, then water and washing with acetone.Vacuum-drying, obtains beige powder (0.5g, 88%)
3) the synthetic chloro-4-of N-[3-(3-fluorine benzyloxy) phenyl] the iodo-quinazoline-4-of-6-amine hydrochlorate
Under nitrogen protection, the stirring and refluxing 3.5h in Virahol (15ml) by chloro-4-6-iodine quinazoline (0.6g, 2mmol) and the chloro-4-of 3-(3-luorobenzyl oxygen base) aniline (0.5g, 2mmol).Be chilled to room temperature, filter, obtain yellow crystal solid (1g, 96%).
4) the synthetic chloro-4-of N-[3-(3-fluorine benzyloxy) phenyl]-6-[(5-formyl radical) furans-2-yl]-4-quinazoline amine
In the mixed solvent of ethylene dichloride (30ml) and methyl alcohol (15ml), add the chloro-4-of N-[3-(3-fluorine benzyloxy) phenyl] the iodo-quinazoline-4-of-6-amine hydrochlorate (1.63g; 3mmol), 5-formylfuran-2-boric acid (0.6g; 4.5mmol), palladium carbon (5%; 0.2g), triethylamine (1.21g; 12mmol), be warming up to 50 ℃ and stir 16h.Through diatomite filtering palladium carbon, filtrate is concentrated, adds ethyl acetate (120ml), tetrahydrofuran (THF) (60ml), water (20ml) and saturated sodium bicarbonate aqueous solution (20ml) in residuum, stirs 15 minutes.Divide and get organic layer, through saturated common salt water washing, anhydrous sodium sulfate drying, concentrated, vacuum-drying, obtains safran solid (1.2g, 86%)
1h NMR (400 MHz, DMSO) δ 10.11 (s, 1H), 9.66 (s, 1H), 8.96 (s, 1H), 8.58 (s, 1H), 8.30 (d,
j=9.0 Hz, 1H), 7.97 (s, 1H), 7.85 (d,
j=8.8 Hz, 1H), 7.74 (d,
j=3.7 Hz, 1H), 7.70 (d,
j=8.7 Hz, 1H), 7.46 (dd,
j=14.2,7.7 Hz, 1H), 7.41 (d,
j=3.7 Hz, 1H), 7.35 – 7.26 (m, 3H), 7.22 – 7.13 (m, 1H), 5.26 (s, 2H).
5) the synthetic chloro-4-of N-[3-(3-fluorine benzyloxy)-phenyl]-6-[5-[(2-thia-6-aza-spiro [3,3] heptane-6-yl) methyl]-furans-2-yl]-quinazoline-4-amine
The chloro-4-of N-[3-(3-fluorine benzyloxy) phenyl]-6-[(5-formyl radical) furans-2-yl]-4-quinazoline amine (1eq), 2-thia-6-aza-spiro [3; 3] heptane oxalate (1eq; first be neutralized into free state with 1.5eq triethylamine) be dissolved in 1; 2-ethylene dichloride (keeping strength of solution ~ 0.5mol/L); after stirring at room temperature half an hour; add acetic acid sodium borohydride (2.5eq), 40 ℃ are stirred 5 hours.Add saturated sodium bicarbonate aqueous solution cancellation reaction, add methylene dichloride and water dilute reaction solution, separatory, organic phase saturated common salt water washing, anhydrous sodium sulfate drying, concentrated, residuum column chromatography purification, obtains safran solid phase prod.
1H NMR (400 MHz, DMSO) δ 9.96 (s, 1H), 8.74 (d,
J = 13.7 Hz, 1H), 8.56 (s, 1H), 8.14 (d,
J = 8.8 Hz, 1H), 8.02 (d,
J = 2.4 Hz, 1H), 7.85 – 7.70 (m, 2H), 7.48 (dd,
J = 14.3, 7.8 Hz, 1H), 7.39 – 7.26 (m, 3H), 7.19 (t,
J = 8.7 Hz, 1H), 7.05 (dd,
J = 11.0, 3.2 Hz, 1H), 6.45 (d,
J = 2.9 Hz, 1H), 5.27 (s, 2H), 4.03 (q,
J = 7.1 Hz, 4H), 3.59 (s, 2H), 3.28 (s, 4H). ESI-MS (m/z): 572.7 [M+H]
+.
Embodiment 2: synthetic compound 2, the chloro-4-of N-[3-(3-fluorine benzyloxy)-phenyl] mix-6-aza-spiro [3,3] heptane-6-yl of-6-[5-[(2-sulfoxide) methyl]-furans-2-yl]-quinazoline-4-amine
The chloro-4-of N-[3-(3-fluorine benzyloxy) phenyl]-6-[(5-formyl radical) furans-2-yl]-4-quinazoline amine (1eq), 2-sulfoxide is assorted-6-aza-spiro [3; 3] heptane oxalate (1eq; first be neutralized into free state with 1.5eq triethylamine) be dissolved in 1; 2-ethylene dichloride (keeping strength of solution ~ 0.5mol/L); after stirring at room temperature half an hour; add acetic acid sodium borohydride (2.5eq), 40 ℃ are stirred 5 hours.Add saturated sodium bicarbonate aqueous solution cancellation reaction, add methylene dichloride and water dilute reaction solution, separatory, organic phase saturated common salt water washing, anhydrous sodium sulfate drying, concentrated, residuum column chromatography purification, obtains safran solid phase prod.
1H NMR (400 MHz, DMSO) δ 9.95 (s, 1H), 8.71 (s, 1H), 8.55 (s, 1H), 8.13 (d,
J = 8.5 Hz, 1H), 8.00 (d,
J = 2.3 Hz, 1H), 7.79 (d,
J = 8.7 Hz, 1H), 7.73 (d,
J = 8.9 Hz, 1H), 7.48 (d,
J = 6.3 Hz, 1H), 7.41 – 7.24 (m, 3H), 7.18 (d,
J = 7.5 Hz, 1H), 7.04 (d,
J = 3.3 Hz, 1H), 6.45 (d,
J = 3.1 Hz, 1H), 5.27 (s, 2H), 3.91 – 3.78 (m, 2H), 3.61 (s, 2H), 3.30 (m, 2H), 3.27 (s, 4H). ESI-MS (m/z): 588.7 [M+H]
+.
Embodiment 3: synthetic compound 3, the chloro-4-of N-[3-(3-fluorine benzyloxy)-phenyl] mix-6-aza-spiro [3,3] heptane-6-yl of-6-[5-[(2-sulfone) methyl]-furans-2-yl]-quinazoline-4-amine
The chloro-4-of N-[3-(3-fluorine benzyloxy) phenyl]-6-[(5-formyl radical) furans-2-yl]-4-quinazoline amine (1eq), 2-sulfone is assorted-6-aza-spiro [3; 3] heptane oxalate (1eq; first be neutralized into free state with 1.5eq triethylamine) be dissolved in 1; 2-ethylene dichloride (keeping strength of solution ~ 0.5mol/L); after stirring at room temperature half an hour; add acetic acid sodium borohydride (2.5eq), 40 ℃ are stirred 5 hours.Add saturated sodium bicarbonate aqueous solution cancellation reaction, add methylene dichloride and water dilute reaction solution, separatory, organic phase saturated common salt water washing, anhydrous sodium sulfate drying, concentrated, residuum column chromatography purification, obtains safran solid phase prod.
1H NMR (400 MHz, DMSO) δ 9.94 (s, 1H), 8.70 (s, 1H), 8.53 (s, 1H), 8.12 (d,
J = 8.9 Hz, 1H), 7.99 (d,
J = 1.8 Hz, 1H), 7.75 (dd,
J = 20.3, 8.8 Hz, 2H), 7.46 (dd,
J = 14.1, 7.8 Hz, 1H), 7.37 – 7.22 (m, 3H), 7.17 (t,
J = 8.6 Hz, 1H), 7.02 (d,
J = 2.7 Hz, 1H), 6.46 (d,
J = 2.6 Hz, 1H), 5.25 (s, 2H), 4.33 (s, 4H), 3.64 (s, 2H), 3.41 (s, 4H). ESI-MS (m/z): 605.2 [M+H]
+.
Embodiment 4: synthetic compound 4, the chloro-4-of N-[3-(3-fluorine benzyloxy)-phenyl]-6-[5-[(1-thia-6-aza-spiro [3,3] heptane-6-yl) methyl]-furans-2-yl]-quinazoline-4-amine
The chloro-4-of N-[3-(3-fluorine benzyloxy) phenyl]-6-[(5-formyl radical) furans-2-yl]-4-quinazoline amine (1eq), 1-thia-6-aza-spiro [3; 3] heptane oxalate (1eq; first be neutralized into free state with 1.5eq triethylamine) be dissolved in 1; 2-ethylene dichloride (keeping strength of solution ~ 0.5mol/L); after stirring at room temperature half an hour; add acetic acid sodium borohydride (2.5eq), 40 ℃ are stirred 5 hours.Add saturated sodium bicarbonate aqueous solution cancellation reaction, add methylene dichloride and water dilute reaction solution, separatory, organic phase saturated common salt water washing, anhydrous sodium sulfate drying, concentrated, residuum column chromatography purification, obtains safran solid phase prod.
1H NMR (400 MHz, DMSO) δ 9.96 (s, 1H), 8.74 (d,
J = 13.7 Hz, 1H), 8.56 (s, 1H), 8.14 (d,
J = 8.8 Hz, 1H), 8.02 (d,
J = 2.4 Hz, 1H), 7.85 – 7.70 (m, 2H), 7.48 (dd,
J = 14.3, 7.8 Hz, 1H), 7.39 – 7.26 (m, 3H), 7.19 (t,
J = 8.7 Hz, 1H), 7.05 (dd,
J = 11.0, 3.2 Hz, 1H), 6.45 (d,
J = 2.9 Hz, 1H), 5.27 (s, 2H), 3.75-3.61 (m, 4H), 3.55 (s, 2H), 3.21--2.96 (m, 4H)；ESI-MS (m/z): 572.6 [M+H]
+。
Embodiment 5: synthetic compound 5, the chloro-4-of N-[3-(3-fluorine benzyloxy)-phenyl] mix-6-aza-spiro [3,3] heptane-6-yl of-6-[5-[(1-sulfoxide) methyl]-furans-2-yl]-quinazoline-4-amine
The chloro-4-of N-[3-(3-fluorine benzyloxy) phenyl]-6-[(5-formyl radical) furans-2-yl]-4-quinazoline amine (1eq), 1-sulfoxide is assorted-6-aza-spiro [3; 3] heptane oxalate (1eq; first be neutralized into free state with 1.5eq triethylamine) be dissolved in 1; 2-ethylene dichloride (keeping strength of solution ~ 0.5mol/L); after stirring at room temperature half an hour; add acetic acid sodium borohydride (2.5eq), 40 ℃ are stirred 5 hours.Add saturated sodium bicarbonate aqueous solution cancellation reaction, add methylene dichloride and water dilute reaction solution, separatory, organic phase saturated common salt water washing, anhydrous sodium sulfate drying, concentrated, residuum column chromatography purification, obtains safran solid phase prod.
1H NMR (400 MHz, DMSO) δ 9.95 (s, 1H), 8.71 (s, 1H), 8.55 (s, 1H), 8.13 (d,
J = 8.5 Hz, 1H), 8.00 (d,
J = 2.3 Hz, 1H), 7.79 (d,
J = 8.7 Hz, 1H), 7.73 (d,
J = 8.9 Hz, 1H), 7.48 (d,
J = 6.3 Hz, 1H), 7.41 – 7.24 (m, 3H), 7.18 (d,
J = 7.5 Hz, 1H), 7.04 (d,
J = 3.3 Hz, 1H), 6.45 (d,
J = 3.1 Hz, 1H), 5.27 (s, 2H), 3.65 (s, 2H), 3.61- 3.42 (m, 4H), 2.62-2.50 (m, 2H), 1.92-1.84 (m, 2H)；ESI-MS (m/z): 588.6 [M+H]
+。
Embodiment 6: synthetic compound 6, the chloro-4-of N-[3-(3-fluorine benzyloxy)-phenyl] mix-6-aza-spiro [3,3] heptane-6-yl of-6-[5-[(1-sulfone) methyl]-furans-2-yl]-quinazoline-4-amine
The chloro-4-of N-[3-(3-fluorine benzyloxy) phenyl]-6-[(5-formyl radical) furans-2-yl]-4-quinazoline amine (1eq), 1-sulfone is assorted-6-aza-spiro [3; 3] heptane oxalate (1eq; first be neutralized into free state with 1.5eq triethylamine) be dissolved in 1; 2-ethylene dichloride (keeping strength of solution ~ 0.5mol/L); after stirring at room temperature half an hour; add acetic acid sodium borohydride (2.5eq), 40 ℃ are stirred 5 hours.Add saturated sodium bicarbonate aqueous solution cancellation reaction, add methylene dichloride and water dilute reaction solution, separatory, organic phase saturated common salt water washing, anhydrous sodium sulfate drying, concentrated, residuum column chromatography purification, obtains safran solid phase prod.
1H NMR (400 MHz, DMSO) δ 9.94 (s, 1H), 8.70 (s, 1H), 8.53 (s, 1H), 8.12 (d,
J = 8.9 Hz, 1H), 7.99 (d,
J = 1.8 Hz, 1H), 7.75 (dd,
J = 20.3, 8.8 Hz, 2H), 7.46 (dd,
J = 14.1, 7.8 Hz, 1H), 7.37 – 7.22 (m, 3H), 7.17 (t,
J = 8.6 Hz, 1H), 7.02 (d,
J = 2.7 Hz, 1H), 6.46 (d,
J = 2.6 Hz, 1H), 5.25 (s, 2H), 3.90- 3.71 (m, 4H), 3.64 (s, 2H), 3.41- 3.3.33 (m, 2H), 2.49-2.28 (s, 2H)；ESI-MS (m/z): 605.1 [M+H]
+。
Embodiment 7: vitro kinase suppresses active testing
Compound utilizes the mobility detection technique (Mobility-Shift Assay) of microfluidic chip technology to complete to EGFR and the kinase whose vitro inhibition active testing of HER2.EGFR and HER-2 kinases are purchased from Carna Biosciences company.
The mobility detection technique (Mobility-Shift Assay) of microfluidic chip technology is applied to the basic concept of capillary electrophoresis in microfluidic environment, with fluorescently-labeled polypeptide for the substrate of testing, in reaction system under the effect of enzyme, substrate changes product into, its with electric charge also there is corresponding variation, Mobility-Shift Assay utilizes substrate and the charged difference of product just, the two is separated, and detect respectively.
The source of strength in micro-fluid chip, sample being separated in two different aspect, electrodynamics and liquid pressure.When work, the reaction system in 384 orifice plates is inhaled in the pipeline of chip internal by the suction needle of chip bottom under the effect of negative pressure.On pipeline, be applied in voltage owing to separating in chip, difference separated with fluorescently-labeled peptide substrate and reaction product due to electric charge, then carries out exciting and detecting of signal at detection window.In the time detecting each sample, can see the signal of substrate and product simultaneously.The amount of product is by calculating Conversion value, i.e. substrate peak and product peak heights sum (Product peak height/(Substrate+Product peak height) in the aspect ratio at product peak), assess.
In the present embodiment, measure respectively positive drug lapatinibditosylate and synthesized compound at 10000nM, 3333nM, 1111nM, 370nM, 123nM, 41nM, 14nM, 4.6nM, active to EGFR and the kinase whose inhibition of HER-2 under ten different concns of 1.5nM and 0.51nM.It is 2.3 μ M that EGFR is adopted to ATP Km value, and it is 7.5 Μ m that HER-2 is adopted to ATP Km value.Calculate compound to EGFR and HER-2 kinase inhibiting activity IC
50value, result is as shown in table 1.Experimental result shows, compound of the present invention demonstrates good kinase inhibiting activity, and wherein compound 2 and 3 is for EGFR kinase inhibiting activity IC
50value is less than 20nM, and compound 2 is for HER-2 kinase inhibiting activity IC
50value is less than 7nM, is better than positive control antitumor drug lapatinibditosylate.Compound of the present invention can further be developed EGFR/HER-2 kinase inhibitor, as new type antineoplastic medicine.
Table 1 is EGFR and the active result of the kinase whose vitro inhibition of HER2 of the compounds of this invention.
Table 1
Embodiment 8: extracorporeal anti-tumor cytoactive test
Get tumour cell kind in Exponential growth stage in 96 orifice plates, cultivate 24 h and make cell attachment, remove supernatant, add 200 μ L/pore area medicine fresh cultures: compound is first dissolved in DMSO or physiological saline, in the time of test, be diluted to desired concn with perfect medium.Each concentration is established 6 multiple holes, and establishes blank hole (only adding substratum) and negative control, establishes equally 6 multiple holes.Continue to be cultured to the test design time, stop cultivating, remove supernatant, every hole adds 10% trichoroacetic acid(TCA) 200 μ L, 4 ℃ of fixing l h of condition.With redistilled water flushing 5 times, naturally dry rear every hole and add 4 mg/mL SRB solution, the 15min that dyes under room temperature, abandons supernatant, with 5 times dyestuffs with removal non-specific binding of 1% acetic acid flushing.Every hole adds 100 μ L 10mM Tris solution, surveys OD value under A490 wavelength, and calculates the inhibiting rate of analyte to growth of cancer cells by following formula.
Control group OD value-treatment group OD value
Control group OD value
And make regression equation with logarithm and the inhibiting rate of compound concentration, calculate IC
50, result shows, compound of the present invention all demonstrates good antineoplastic activity (as shown in table 2), for the anti tumor activity in vitro IC of NCI-N87 stomach cancer cell, BT-474 breast cancer cell and SKBr-3 breast cancer cell
50value is nM level, and wherein compound 2 is for the extracorporeal anti-tumor IC of NCI-N87 stomach cancer cell
50value is 12nM, and compound 1-6 is for the extracorporeal anti-tumor IC of BT-474 breast cancer cell
50value is all less than 1.6nM, and compound 2 is for the extracorporeal anti-tumor IC of SKBr-3 breast cancer cell
50value, for 15.3nM, is better than positive control antitumor drug lapatinibditosylate, can further prepare new type antineoplastic medicine.
Table 2 is extracorporeal anti-tumor cytoactive results of the compounds of this invention.
Table 2
| Compound | Suppress the active IC of NCI-N87 stomach cancer cell 50（nM） | Suppress the active IC of BT-474 breast cancer cell 50（nM） | Suppress the active IC of SKBr-3 breast cancer cell 50（nM） |
| 1 | 27.1 | < 1.6 | 29.0 |
| 2 | 12.0 | < 1.6 | 15.3 |
| 3 | 21.6 | < 1.6 | 31.5 |
| 4 | - | < 1.6 | - |
| 5 | - | < 1.6 | - |
| 6 | - | < 1.6 | - |
| Lapatinibditosylate | 12.4 | 7.8 | 15.5 |
Claims (10)
1. sulfur-bearing 6-furyl quinazoline-4-amine compound, it is characterized in that, described compound is the chloro-4-[(3-fluorophenyl of N-[3-containing sulfo-quaternary heterocycle or spirane structure) methoxyl group] phenyl]-6-(2-furyl) quinazoline-4-aminated compounds, there is the structure of general formula (I)
Wherein X=H or S or SO or SO
2,
Y=H or S or SO or SO
2.
2. sulfur-bearing 6-furyl quinazoline-4-amine compound according to claim 1, is characterized in that, described compound is the compound 1 with following structure,
1 。
3. sulfur-bearing 6-furyl quinazoline-4-amine compound according to claim 1, is characterized in that, described compound is the compound 2 with following structure,
2 。
4. sulfur-bearing 6-furyl quinazoline-4-amine compound according to claim 1, is characterized in that, described compound is the compound 3 with following structure,
3 。
5. sulfur-bearing 6-furyl quinazoline-4-amine compound according to claim 1, is characterized in that, described compound is the compound 4 with following structure,
4 。
6. sulfur-bearing 6-furyl quinazoline-4-amine compound according to claim 1, is characterized in that, described compound is the compound 5 with following structure,
5 。
7. sulfur-bearing 6-furyl quinazoline-4-amine compound according to claim 1, is characterized in that, described compound is the compound 6 with following structure,
6 。
8. the purposes of sulfur-bearing 6-furyl quinazoline-4-amine compound of claim 1 in preparation EGFR and HER-2 kinase inhibitor.
9. the purposes of sulfur-bearing 6-furyl quinazoline-4-amine compound of claim 1 in preparation treatment malignant tumor medicine.
10. by the purposes of claim 9, it is characterized in that, described malignant tumour is the related neoplasms due to Tyrosylprotein kinase functional disorder, comprises the cancer of the brain, lung cancer, kidney, osteocarcinoma, liver cancer, bladder cancer, cancer of the stomach, carcinoma of the pancreas, mammary cancer, incidence cancer, esophagus cancer, prostate cancer, colorectal carcinoma, ovarian cancer, cervical cancer or thyroid carcinoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310156310.8A CN103772411B (en) | 2013-04-28 | 2013-04-28 | Sulfur-bearing 6-furyl quinazoline-4-amines and its production and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310156310.8A CN103772411B (en) | 2013-04-28 | 2013-04-28 | Sulfur-bearing 6-furyl quinazoline-4-amines and its production and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103772411A true CN103772411A (en) | 2014-05-07 |
| CN103772411B CN103772411B (en) | 2016-08-03 |
Family
ID=50565226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310156310.8A Expired - Fee Related CN103772411B (en) | 2013-04-28 | 2013-04-28 | Sulfur-bearing 6-furyl quinazoline-4-amines and its production and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103772411B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114929704A (en) * | 2019-12-27 | 2022-08-19 | 微境生物医药科技(上海)有限公司 | Spiro-containing quinazoline compounds |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2345486A (en) * | 1999-01-11 | 2000-07-12 | Glaxo Group Ltd | Heteroaromatic protein tyrosine kinase inhibitors |
| CN102108079A (en) * | 2009-12-25 | 2011-06-29 | 齐鲁制药有限公司 | 4-anilino quinazoline derivatives serving as tyrosine kinase inhibitors |
| CN102711472A (en) * | 2009-07-02 | 2012-10-03 | 纽金药物公司 | Phosphorus containing quinazoline compounds and methods of use |
| WO2013017073A1 (en) * | 2011-08-01 | 2013-02-07 | 杭州民生药物研究所有限公司 | Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament |
-
2013
- 2013-04-28 CN CN201310156310.8A patent/CN103772411B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2345486A (en) * | 1999-01-11 | 2000-07-12 | Glaxo Group Ltd | Heteroaromatic protein tyrosine kinase inhibitors |
| CN102711472A (en) * | 2009-07-02 | 2012-10-03 | 纽金药物公司 | Phosphorus containing quinazoline compounds and methods of use |
| CN102108079A (en) * | 2009-12-25 | 2011-06-29 | 齐鲁制药有限公司 | 4-anilino quinazoline derivatives serving as tyrosine kinase inhibitors |
| WO2013017073A1 (en) * | 2011-08-01 | 2013-02-07 | 杭州民生药物研究所有限公司 | Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament |
Non-Patent Citations (1)
| Title |
|---|
| GAUTAM PATEL等: "Kinase Scaffold Repurposing for Neglected Disease Drug Discovery:Discovery of an Efficacious, Lapatanib-Derived Lead Compound for Trypanosomiasis", 《JOURNAL OF MEDICINAL CHEMISTRY》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114929704A (en) * | 2019-12-27 | 2022-08-19 | 微境生物医药科技(上海)有限公司 | Spiro-containing quinazoline compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103772411B (en) | 2016-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11007197B2 (en) | EGFR modulators and uses thereof | |
| RU2645672C2 (en) | New compounds of pyrrolopyrimidine as inhibitors of protein kinases | |
| CN105237515B (en) | Deuterated pyrimidines, its preparation method, pharmaceutical composition and purposes | |
| WO2016168992A1 (en) | Preparation and use of novel protein kinase inhibitors | |
| JP7312335B2 (en) | 4-Oxo-3,4-dihydroquinazolinone compounds for treating BRAF-related diseases and disorders | |
| JP2022539056A (en) | Quinazolin-4-one Derivatives Useful for Treating BRAF-Related Diseases and Disorders | |
| KR20160121520A (en) | Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors | |
| EP2121634A1 (en) | Pyrimidine-2,4-diamine derivatives and their use as jak2 kinase inhibitors | |
| CN103848829A (en) | Heteroaryl alkyne compounds and application thereof | |
| US11643421B2 (en) | Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer | |
| WO2021074251A1 (en) | Pyrrolo[2,3-d]pyrimidine derivatives and their use in the treatment of cancer | |
| JP2022515880A (en) | Quinoline compounds as inhibitors of TAM and MET kinase | |
| WO2020001351A1 (en) | Egfr inhibitor, method for preparing the same, and uses thereof | |
| Zhou et al. | Design, synthesis and evaluation of anti-proliferative activity of 2-aryl-4-aminoquinazoline derivatives as EGFR inhibitors | |
| EP3663285A1 (en) | Formylpyridine derivative having fgfr4 inhibitory activity, preparation method therefor and use thereof | |
| CN103965119A (en) | Zinc binding group-containing irreversible EGFR tyrosine kinase inhibitor | |
| CN103772411A (en) | Chemical compound containing sulphur-6-furyl chinazoline-4-amine and preparation method and application thereof | |
| JP6826526B6 (en) | Quinoxaline compounds, how to prepare them and their use | |
| CN106916112B (en) | Pyrimidine derivative, preparation method and medical application thereof | |
| CN105585557B (en) | EGFR inhibitor for targeted therapy of cancer and preparation method and application | |
| CN104151321B (en) | N-(2-chloro-6-aminomethyl phenyl)-2 [(2-methylpyrimidine-4-base) amino] thiazole-5-methanamide compound and its production and use | |
| CN103509024B (en) | Kui Linpyrimido quinoline benzazepine compounds and the application as antitumor drug thereof | |
| CN103772371A (en) | 6-furyl quinazoline-4-amine compound as well as preparation method and application thereof | |
| Cui et al. | Structure optimization and discovery of novel compound for the treatment of insertion mutations within exon 20 of EGFR and HER2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160803 Termination date: 20190428 |